Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/98cade41-fe6f-4f1c-8211-b2e42cd2c12c/

VRXA

Veraxa Biotech AG Ordinary Shares
Chart
2.20 USD
Latest Week 2026-07-10
Snapshot 2026-07-12 · 0.6w · Fresh
0.31
OS Score
41.0%
Value
39.0%
Quality
42.0%
Momentum
2/9
F-Score
0.400
QV
Strategy Eligibility
0 of 23 passing
OS Composite
Trending Value
Quality × Value
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
VC2 Cheapest
📐
EBITDA/EV
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
📈
Consistent Earners
🌱
GARP
🔄
Shareholder Yield
💰
High Yield
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
Risk-Adj Momentum
V
Value Analysis
Cheapness relative to fundamentals
41.0%ile
FCF Yield
-0.030
SH Yield
-0.019
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
60.00000000
/100 — 1=cheapest
VC2 (Trending Value)
60.00000000
/100
VC3 (Buyback)
60.00000000
/100
Negative FCF yield (-3.0%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
39.0%ile
ROE
4.225
ROA
-0.824
Net Margin
-2843.592
Op Margin
-2826.627
GPA
0.000
D/E
-6.13
Current
0.44
F-Score
2/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.000
Accruals
-0.702
lower=better
5yr Consist
No
ROE of 423% is exceptional. Conservative balance sheet with D/E of -6.13. F-Score of 2/9 flags fundamental deterioration — multiple signals are weakening.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
42.0%ile
Max DD 12M
-89.8%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
OS
Composite & Factor Heatmap
All factors at a glance
0.31
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
11.2%
Sector Quality %ile
8.2%
Sector Avg OS
64.4%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
NUTX Nutex Health Inc 99.0% 90.0% 98.0% 86.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 90.0%
TBPH Theravance Biopharma Inc 99.0% 90.0% 99.0% 88.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 89.0% 93.0% 94.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 95.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 90.0% 91.0% 98.0%
CGEN Compugen 98.0% 89.0% 96.0% 85.0%
INVA Innoviva Inc 98.0% 94.0% 94.0% 75.0%
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
0.0% avg (2 factors)
Quality
D
37.5% avg (8 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends5 snapshots
Factor Persistence5 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.310—0
Value %ile0.410—0
Quality %ile0.390—0
Momentum %ile0.420—0
F-Score2.000—5
Confidence0.458—0
Volatility—0
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
FCF Yield
-3.0%
Sales Yield (1/P·S)
0.0001
Shareholder Yield
Div + net buyback / mktcap
-1.9%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
422.5%
Return on Assets
-82.4%
Net Margin
-284359.2%
Operating Margin
-282662.7%
Gross Profit / Assets
Novy-Marx GPA
0.0%
Debt / Equity
-6.13
Current Ratio
0.44
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.702
MomentumPrice trend strength over different horizons
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
0.0%
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
2
Buyback Yield
-1.9%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
60
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
60
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
60
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity